Quercetin
Quercetin is a ubiquitous dietary flavonol found in onions, apples, berries, and capers that has emerged as one of the most pharmacologically versatile polyphenols in biomedicine, with documented activities spanning NF-κB inhibition, AMPK activation, PI3K/AKT modulation, mast cell stabilization, and senolytic activity in combination with dasatinib. Its interactions with 48 gene targets reflect broad pleiotropic activity across inflammation, autophagy, cancer signaling, and cellular senescence pathways, with oral bioavailability substantially improved by phytosome or quercetin phytosomes formulations.
Key Takeaways
- •A flavonol (3-hydroxyflavone) abundantly found in onions, apples, capers, berries, and green tea; one of the most widely consumed dietary polyphenols globally with a long history of traditional use and over 10,000 published research articles.
- •Primary mechanisms include NF-κB inhibition through IKK and p38 MAPK suppression, AMPK activation mimicking mild energy stress, PI3K/AKT pathway modulation, and CD38 inhibition contributing to NAD+ preservation and anti-inflammatory effects.
- •Senolytic activity: quercetin combined with dasatinib (D+Q protocol) selectively eliminates senescent cells expressing p16INK4a (CDKN2A), an approach in Phase I clinical trials for age-related conditions; quercetin alone may have modest senolytic activity at higher concentrations.
- •Mast cell stabilization through KIT signaling modulation and downstream kinase inhibition reduces histamine and inflammatory mediator release, supporting quercetin's traditional use for allergy and respiratory conditions.
- •Bioavailability is low for quercetin aglycone (5 to 17%), with rapid intestinal metabolism to glucuronide and sulfate conjugates; quercetin glycosides from food have better absorption than pure quercetin; phytosome and quercetin phytosomes formulations improve systemic exposure.
- •Well-tolerated at doses of 500 to 1,000 mg per day in clinical trials; potential interactions with CYP enzyme substrates and anticoagulants at higher doses require attention.
- •For senolytic and broad anti-aging applications, the intermittent D+Q protocol (dasatinib 100 mg plus quercetin 1,000 mg for 2 consecutive days, repeated monthly) is the clinically studied approach; daily supplementation at 500 to 1,000 mg supports anti-inflammatory and AMPK-activating effects.
Basic Information
- Name
- Quercetin
- Also Known As
- Quercetin aglyconeQuercetol3,3',4',5,7-pentahydroxyflavoneQuercetin dihydrateSophora japonica extract
- Category
- Flavonol / Dietary polyphenol
- Bioavailability
- Quercetin aglycone has approximately 5 to 17% oral bioavailability; quercetin glycosides (rutin, quercetin-3-glucoside) from food are generally better absorbed. Phase II metabolism (glucuronidation, sulfation) in the intestinal mucosa and liver produces conjugated metabolites that retain partial biological activity. Quercetin phytosomes and quercetin-lecithin complexes improve absorption 5- to 20-fold compared to standard powder.
- Half-Life
- Plasma half-life of quercetin aglycone is approximately 11 to 28 hours after absorption, with glucuronide conjugates persisting longer. Repeated daily dosing achieves stable plasma concentrations. Food sources provide quercetin as glycosides with different absorption kinetics than supplemental pure quercetin.
Quick Safety Summary
Clinical trials have used 500 mg to 1,000 mg per day for anti-inflammatory applications; the D+Q senolytic protocol uses 1,000 mg quercetin plus 100 mg dasatinib for 2 consecutive days per month. Most studies use 500 to 1,000 mg/day as a daily supplement. Doses above 1,000 mg/day are generally not studied for chronic daily use.
Avoid with iron-deficiency anemia when taken concurrently with iron-containing foods or supplements, as quercetin chelates dietary iron and may impair absorption; separate timing by at least 2 hours., The D+Q senolytic protocol requires medical supervision; dasatinib has significant drug interactions and toxicities requiring clinical oversight., Use with caution during pregnancy due to theoretical concerns about estrogen receptor activity and insufficient safety data for supplemental doses.
Overview
Quercetin is a flavonol (3-hydroxyflavone) polyphenol found in virtually every plant-based food, with highest concentrations in capers, red onions, lovage, and elderberries, and appreciable amounts in apples, broccoli, kale, and green tea. It is one of the most abundant dietary polyphenols in Western diets, with estimated average intake of 10 to 50 mg per day from food. As a supplement, quercetin has gained substantial research attention due to its broad pharmacological activity profile, encompassing anti-inflammatory, antioxidant, antiviral, anticancer, autophagy-inducing, and senolytic properties. Few natural compounds demonstrate activity across as many disease-relevant molecular pathways as quercetin, making it one of the most intensively studied flavonoids in biomedicine.
The molecular pharmacology of quercetin is defined by its hydroxyl-rich structure, which enables both direct radical scavenging and interaction with multiple enzymatic and receptor targets. Its most consequential cellular mechanisms include: inhibition of IKKβ to suppress NF-κB inflammatory cascades; activation of AMPK through LKB1-dependent pathways to promote metabolic stress adaptation; inhibition of PI3K p110 subunit catalytic activity to modulate AKT-mTOR signaling; CD38 inhibition contributing to preservation of cellular NAD+ pools; mast cell stabilization through KIT/PI3K pathway suppression; and activation of NRF2 to induce antioxidant enzyme expression including NQO1 and HO-1. This multi-target pharmacology reflects the polyphenol's ability to interact with diverse protein structural motifs through hydrogen bonding and hydrophobic interactions.
The senolytic application of quercetin represents one of its most clinically exciting emerging uses. Senescent cells accumulate with aging and disease, secreting the senescence-associated secretory phenotype (SASP) of pro-inflammatory cytokines, matrix metalloproteases, and growth factors that damage surrounding tissue. These cells resist apoptosis through upregulation of BCL-2 family survival proteins, MDM2-mediated p53 suppression, and FOXO4-p21 nuclear retention. The combination of dasatinib (a BCR-ABL/Src kinase inhibitor) and quercetin (D+Q) targets these survival mechanisms from complementary angles, inducing selective apoptosis of senescent cells. Phase I clinical trials have demonstrated D+Q efficacy in idiopathic pulmonary fibrosis, diabetic kidney disease, and frailty in elderly individuals, with measurable reductions in circulating SASP biomarkers and improvements in physical function.
Bioavailability is the primary limitation of quercetin supplementation. Standard quercetin aglycone powder absorbs poorly (5 to 17%) due to limited intestinal solubility and rapid phase II conjugation. Food-derived quercetin glycosides (quercetin-3-glucoside from onions, rutin from buckwheat) are hydrolyzed by intestinal microbiota to release the aglycone, which then absorbs with somewhat better consistency. Phytosome-complexed quercetin (quercetin bound to phosphatidylcholine) and liposomal formulations substantially improve bioavailability. For anti-inflammatory and AMPK-activating benefits, daily supplementation at 500 to 1,000 mg is supported by clinical trials. For senolytic applications, the intermittent D+Q protocol used in clinical trials is preferable to daily dosing, as senescent cell elimination requires a pulse of sufficient concentration rather than chronic low-level exposure.
Core Health Impacts
- • Anti-inflammatory and NF-κB suppression: Quercetin inhibits multiple nodes in the NF-κB activation cascade including IKKβ kinase activity, IκBα degradation, and downstream inflammatory cytokine transcription (TNF-α, IL-6, IL-1β, MCP-1). It additionally suppresses p38 MAPK and JNK to reduce MAPK-driven inflammatory amplification. These effects converge to reduce chronic low-grade inflammation relevant to metabolic disease, autoimmune conditions, and cardiovascular aging.
- • Senolytic activity: Quercetin (typically combined with dasatinib as D+Q) eliminates senescent cells by interfering with the senescent cell anti-apoptotic pathways (SCAPs) that include PI3K/AKT, BCL-2 family survival proteins, and p21-driven cell cycle arrest. Senescent cells express high BCL-2L1, MDM2, and FOXO4 that quercetin and dasatinib target; their selective elimination reduces the senescence-associated secretory phenotype (SASP) and associated tissue dysfunction.
- • AMPK activation and metabolic support: Quercetin activates AMPK through LKB1 (STK11)-dependent mechanisms, mimicking mild energy stress and promoting glucose uptake, fatty acid oxidation, and mitochondrial biogenesis via PGC-1α. This AMPK activation also inhibits mTOR, reducing anabolic signaling and promoting autophagy, providing a caloric restriction-like metabolic effect.
- • Mast cell stabilization and allergy management: Quercetin stabilizes mast cells by inhibiting KIT receptor signaling and downstream PI3K/AKT pathway required for IgE-triggered degranulation. This reduces histamine, tryptase, and leukotriene release, supporting management of allergic rhinitis, atopic dermatitis, and asthma symptoms. The KIT stabilization mechanism distinguishes quercetin from most antihistamines.
- • Antioxidant and NQO1 induction: Quercetin directly scavenges free radicals through its polyhydroxyl structure and chelates metal ions (iron, copper) that catalyze oxidative reactions. It also activates NRF2, inducing NQO1, HO-1, and other phase II antioxidant enzymes. NQO1 in turn can reduce quercetin quinones, creating a redox cycle that amplifies antioxidant capacity and supports cellular oxidative stress management.
- • Autophagy and proteostasis: Quercetin activates autophagy through AMPK/mTOR axis modulation and by supporting BECN1-dependent autophagosome formation. This promotes clearance of misfolded protein aggregates relevant to neurodegenerative disease and cellular aging. The combination of autophagy induction and senolytic activity positions quercetin as a broad proteostasis-supporting compound.
- • Iron regulation: Quercetin chelates free iron through its catechol groups and can influence hepcidin-ferroportin signaling relevant to systemic iron homeostasis. This iron-chelating activity contributes to its antioxidant effects (reducing Fenton chemistry) and may be relevant in conditions of iron overload, though it can also reduce dietary iron absorption when taken concurrently with iron-rich meals.
Gene Interactions
Key Gene Targets
AKT1
A flavonoid that influences PI3K/AKT kinase pathways by interfering with PI3K p110 catalytic activity and AKT Ser473 phosphorylation, reducing pro-survival and pro-growth signaling downstream of receptor tyrosine kinases.
BCL2L1
Acts as a weak senolytic by interfering with BCL-XL (BCL2L1)-mediated survival signaling in senescent cells, contributing to the D+Q protocol's ability to selectively eliminate p16-high or p21-high senescent cell populations.
CD38
Reported direct CD38-inhibitory activity that reduces CD38-mediated NAD+ hydrolysis, contributing to anti-inflammatory effects and NAD+ preservation; CD38 inhibition by quercetin may synergize with NAD+ precursor supplementation.
CDKN2A
Used alongside dasatinib (D+Q protocol) as a senolytic to selectively eliminate p16INK4a (CDKN2A)-expressing senescent cells through interference with their anti-apoptotic survival pathways, reducing SASP-driven tissue inflammation.
NFKB1
Modulates multiple inflammatory kinases upstream of NF-κB including IKKβ activity and IκBα degradation, as well as p38 MAPK and JNK activity, providing broad suppression of NF-κB-driven inflammatory cytokine transcription.
STK11
Known to stimulate the LKB1 (STK11)-AMPK pathway through mechanisms that mimic mild energy stress, making STK11 a required upstream kinase for the full AMPK-activating effects of quercetin in most cellular contexts.
MTOR
A senolytic flavonoid that inhibits mTOR signaling through AMPK-dependent TSC1/TSC2 activation and direct mTOR complex modulation, particularly targeting the elevated mTOR activity that drives SASP secretion in senescent cells.
Safety & Dosing
Contraindications
Avoid with iron-deficiency anemia when taken concurrently with iron-containing foods or supplements, as quercetin chelates dietary iron and may impair absorption; separate timing by at least 2 hours.
The D+Q senolytic protocol requires medical supervision; dasatinib has significant drug interactions and toxicities requiring clinical oversight.
Use with caution during pregnancy due to theoretical concerns about estrogen receptor activity and insufficient safety data for supplemental doses.
Drug Interactions
Warfarin and anticoagulants: quercetin may inhibit CYP2C9, potentially elevating warfarin levels; monitor INR when combining
CYP3A4 substrates: quercetin inhibits CYP3A4 at higher doses; plasma levels of co-administered CYP3A4-metabolized drugs may be elevated
Quinolone and tetracycline antibiotics: quercetin chelation may reduce antibiotic absorption; separate timing by 2 to 3 hours
Cyclosporine and other P-glycoprotein substrates: quercetin inhibits P-gp, potentially increasing drug bioavailability
Common Side Effects
Mild GI discomfort (nausea, headache, tingling in extremities) at doses above 1,000 mg per day, more common with lower-quality formulations
Theoretical concern about kidney stone formation at very high doses due to quercetin metabolite excretion; adequate hydration recommended
Studied Doses
Clinical trials have used 500 mg to 1,000 mg per day for anti-inflammatory applications; the D+Q senolytic protocol uses 1,000 mg quercetin plus 100 mg dasatinib for 2 consecutive days per month. Most studies use 500 to 1,000 mg/day as a daily supplement. Doses above 1,000 mg/day are generally not studied for chronic daily use.
Mechanism of Action
NF-κB Suppression and Anti-inflammatory Activity
Quercetin inhibits IKKβ kinase activity, preventing IκBα phosphorylation and subsequent NF-κB nuclear translocation. It additionally suppresses p38 MAPK and JNK activation by modulating upstream MAPK kinase activity. These combined effects reduce transcription of TNF-α, IL-6, IL-1β, and MCP-1, the primary mediators of chronic low-grade inflammation. Quercetin’s NF-κB inhibition is particularly potent in macrophages and mast cells.
AMPK Activation and mTOR Suppression
Quercetin activates AMPK through LKB1-dependent mechanisms by increasing the cellular AMP/ATP ratio through mild mitochondrial inhibition and through indirect mechanisms involving SIRT1. AMPK activation phosphorylates and activates TSC1/TSC2, suppressing mTORC1 and promoting autophagy through ULK1 dephosphorylation. This mTOR inhibition in senescent cells is a central mechanism of quercetin’s senolytic activity.
Senolytic Activity in the D+Q Protocol
Senescent cells upregulate PI3K/AKT-driven survival signals and BCL-2 family anti-apoptotic proteins to resist apoptosis. Quercetin interferes with AKT-mediated survival signaling and BCL-2L1-driven apoptosis resistance, while dasatinib targets Src family kinase and BCR-ABL survival pathways in a complementary manner. Together, D+Q eliminates senescent cells while sparing normal proliferating cells, reducing the SASP and its associated tissue toxicity.
Clinical Evidence
Clinical trials support quercetin’s anti-inflammatory effects in metabolic syndrome (reduced triglycerides, improved glucose), antihypertensive activity (meta-analyses show approximately 3.04 mmHg systolic reduction at doses above 500 mg/day), and mast cell stabilization for allergy management. The D+Q senolytic protocol has completed Phase I trials in IPF, diabetic kidney disease, and elderly frailty, showing measurable reductions in senescent cell burden and SASP biomarkers with improvements in physical performance. Larger Phase II trials are ongoing. Bioavailability limitations mean that dose selection and formulation choice significantly affect clinical outcomes, with phytosome-complexed quercetin showing the most consistent systemic exposure.
Relevant Research Papers
Links go to PubMed (abstracts are public); some papers also offer free full text via PMC or the publisher.
Comprehensive review establishing the mechanisms of quercetin's mast cell stabilization and anti-allergic activity, including KIT pathway modulation, histamine suppression, and Th2 cytokine attenuation relevant to allergic rhinitis and asthma management.
First human clinical trial of the D+Q senolytic protocol in IPF patients, demonstrating feasibility, tolerability, and reductions in circulating senescent cell burden (adipose tissue p16INK4a+ cells) and SASP biomarkers, establishing proof-of-concept for senolytic therapy.
RCT in metabolic syndrome patients showing that 500 mg/day quercetin for 10 weeks significantly reduced serum triglycerides, LDL cholesterol, and fasting blood glucose while improving HDL, confirming metabolic benefits through AMPK and PPAR pathway activation.
Demonstrated that quercetin and its conjugated metabolites inhibit platelet activation, reduce hydroxyl radical generation, and provide antioxidant platelet protection relevant to cardiovascular thrombosis prevention.
Mechanistic study demonstrating that quercetin reduces adipose tissue macrophage infiltration and inflammation through AMPK-alpha1/SIRT1 activation, reducing inflammatory cytokines and improving insulin sensitivity in obese mice.